Global pharma major, Lupin Limited (Lupin) announced that they have entered into a licensing agreement with Alvion Pharmaceuticals P.C. (Alvion) to commercialize medicines for Cardiometabolic diseases in the Southeast Asia region.

Lupin is committed to providing new affordable treatment options to healthcare providers and patients. By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin will play a significant role in improving the quality of healthcare and access to medicines.

Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region